And likewise the cup after they had eaten, saying, ‘This cup is the new covenant in my blood, which will be shed for you’” (Luke 22:19-20). Here we have Jesus instituting the Eucharist and ...

Based on work over the last 18 months, we are adopting a revised Covenant for Life Together in 2025. For students, this updated Covenant will begin with the 2025-2026 academic year. Until then, please ...

As news broke of a shooting inside a Nashville high school on Wednesday, parents impacted by the Covenant School shooting two years ago say they are heartbroken and "sickened" to see another young ...

Covenant in the works, Michael Fassbender definitely wants to be a part of it. The actor spoke to Esquire last week about the biggest roles of his career, including playing the androids David 8 and ...

NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular ...

SAN DIEGO, Jan. 14, 2025 /PRNewswire/ -- Neomorph, Inc., today announced the appointment of Dr. Klaus Wagner as Chief Medical Officer. Dr. Wagner is a seasoned biotech executive with extensive ...

The City of Edmond said it is vowing to do better after a longtime resident made the city council aware of an illegal, discriminatory, restrictive covenant from an existing plat document. " ...

"At Neomorph, we have spent years building a unique molecular glue platform with broad coverage of the proteome," said Phil Chamberlain, DPhil, Co-Founder, President, and Chief Executive Officer ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform.

The North Chicago-based company announced today it entered into an option-to-license agreement with San Diego-based Neomorph to develop novel therapies for cancers and immune diseases. Neomorph ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion in milestone payments. AbbVie and Neomorph have announced a collaboration ...

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and immunology, with the deal worth $1.64bn. The collaboration and ...